On the other hand, identification of regulators of such ubiquitination processes, such as WWP2, is essential for the development of novel therapies in pathologies where blood flow is altered, as drugs blocking disease‐specific posttranslational modifications such as protein ubiquitination could have low toxicity compared to conventional drugs, and be beneficial for patients with cardiovascular diseases, where therapeutic options are often limited.[57] Further studies are necessary to investigate the therapeutic potential of these novel regulators of endothelial response to flow.[58]. This evidence concerns the gene WWP2 and cardiovascular disorder.